Coronary Artery Bypass Graft Surgery

BOSTON — In the all-comers SCAAR registry of patients with left main CAD who underwent revascularization in Sweden, PCI was associated with higher mortality rates compared with CABG.

BOSTON — At a median follow-up of 11.8 years, most outcomes did not differ between PCI with an everolimus-eluting stent and CABG in patients with multivessel CAD, according to new data from the BEST trial.

Data from a retrospective analysis show there are significant differences in the types of complex high-risk PCI cases undertaken across centers in England and Wales, as well as differences in clinical outcomes across age groups.

Compared with aspirin alone, aspirin plus ticagrelor was associated with reduced risk for vein graft failure and increased risk for clinically important bleeding in patients who underwent CABG, according to a meta-analysis.

Among patients undergoing elective CABG, infusion of high-dose tranexamic acid modestly reduced the need for red blood cell transfusion and was noninferior to low-dose infusion regarding safety, findings show.

A 4% albumin solution for priming and perioperative IV volume replacement solution in CABG did not reduce risk for 90-day major adverse events compared with standard Ringer’s acetate solution, researchers reported.

Early revascularization may confer mortality benefit in patients with moderate to severe myocardial ischemia identified on nuclear stress testing, regardless of left ventricular ejection fraction, researchers reported.

Among octogenarians, patients who underwent CABG had longer survival times compared with age- and sex-matched individuals who did not, researchers reported in Mayo Clinic Proceedings.

Women and adults who reside in low-income areas are more likely to die 30 days after cardiac surgery compared with men and those living in higher-income ZIP codes, according to a nationwide database analysis.

WASHINGTON — In patients with three-vessel CAD, those who underwent fractional flow reserve-guided PCI had similar quality of life at 1 year compared with those who underwent CABG, according to new data from the FAME 3 trial.